Bacteria are getting to be resistant to therapy as consumption develops. Resistance undermines much of contemporary healthcare, which relies on access to antibiotics to prevent and treat ailments associated with medical procedures. The challenges have much in common with those posed by climate change, which economists have responded to with research which has informed and shaped public policy. Drawing on concepts like the principal and externalities –agent relationship, we suggest how economics can help solve the challenges arising from increasing resistance to antibiotics. We talk about solutions to the key financial problems, from incentivizing the development of powerful new antibiotics into improving stewardship through mechanisms and regulation.